ACE trial design: Equol targeting estrogen receptor-β in vascular and cognitive aging.

ABSTRACT:

Introduction

Equol, a gut microbiome-derived metabolite of soy isoflavone daidzein, functions as a selective estrogen receptor beta (ERβ) agonist. In preclinical studies, it has demonstrated vascular protective and antioxidant effects, with emerging evidence suggesting potential neuroprotective properties. However, its role in preventing vascular aging and cognitive decline in humans remains unexplored. The Arterial Stiffness, Cognition, and Equol (ACE) trial investigates whether daily equol supplementation can slow the progression of arterial stiffness, brain white matter lesions, and cognitive decline in older adults without dementia.

Methods

ACE is a multicenter, randomized, double-blind, placebo-controlled clinical trial conducted at the University of Pittsburgh, Wake Fo

SUBMITTER: Sekikawa A 

PROVIDER: S-EPMC12361350 | biostudies-literature | 2025 Jul-Sep

REPOSITORIES: biostudies-literature